10. Immunosuppressive Pharmacotherapy

  1. Nizam Mamode4 and
  2. Raja Kandaswamy5
  1. Steven Gabardi1,2 and
  2. Anil Chandraker3

Published Online: 23 DEC 2012

DOI: 10.1002/9781118483664.ch10

Abdominal Organ Transplantation: State of the Art

Abdominal Organ Transplantation: State of the Art

How to Cite

Gabardi, S. and Chandraker, A. (2013) Immunosuppressive Pharmacotherapy, in Abdominal Organ Transplantation: State of the Art (eds N. Mamode and R. Kandaswamy), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781118483664.ch10

Editor Information

  1. 4

    Guy's and St Thomas' Hospital, Great Ormond Street Hospital, London, UK

  2. 5

    Department of Surgery, University of Minnesota, Minneapolis, MN, USA

Author Information

  1. 1

    Renal Division/Departments of Transplant Surgery and Pharmacy Services, Brigham and Women's Hospital; and Department of Medicine, Harvard Medical School, USA

  2. 2

    Department of Medicine, Harvard Medical School, USA

  3. 3

    Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Publication History

  1. Published Online: 23 DEC 2012
  2. Published Print: 12 FEB 2013

ISBN Information

Print ISBN: 9781444334326

Online ISBN: 9781118483664



  • Antiproliferatives;
  • Calcineurin Inhibitors;
  • Corticosteroids;
  • Co-Stimulation Blockade;
  • Immunosuppression;
  • Immunosuppressants;
  • Induction Therapy;
  • Maintenance Therapy;
  • Target of Rapamycin Inhibitors


The primary objective of clinical immunosuppression following renal transplantion is to prevent acute rejection while limiting the complications of the immunosuppressive agents. A balance between over- and under-immunosuppression can be difficult to achieve and has significant consequences if not accomplished. Under-immunosuppression can result in allograft rejection, while over-immunosuppression can result in complications such as infection and malignancy. Local protocols and national/international guidelines have been developed to help create immunosuppressive regimens; however, the final decision on the most appropriate immunosuppressive therapy in an individual transplant recipient is highly dependent on a practitioner's experience, pre-existing medical conditions and donor characteristics.